Clinical studies of high-dose methylprednisolone in the treatment of acute pancreatitis short merger of systemic inflammatory response syndrome

high-dose methylprednisolone treatment in patients with acute pancreatitis with systemic inflammatory response syndrome: A randomized, parallel-group, single-center, double-blind and prospective study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004942

Enrollment

Unknown

Registered

2014-05-04

Start date

2014-07-14

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute pancreatitis

Interventions

Methylprednisolone group:Internal medicine treatment and Methylprednisolone

placebo group:Internal medicine treatment

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years; 2. Male or female; 3. Onset shorter than 72h; 4. Diagnosed with AP and at the same time meet the diagnostic criteria for SIRS hospitalized patients; 5. Patients or their families consented to participate in the study and signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. glucocorticoid drug allergy; 2. history of severe mental illness, epilepsy; 3. active peptic ulcer, nearly six months of surgery, trauma healed; 4. severe hypertension, diabetes, hyperlipidemia, in the case of poorly controlled drugs; 5. failed to control the infection, such as tuberculosis, active hepatitis, chicken pox, and fungal infections; 6. severe osteoporosis; 7. pregnancy, breast-feeding women; 8. chronic renal failure caused by organic kidney disease; 9. Use in patients with peritoneal lavage; 10. before the onset of January corticosteroids were used; 11. by using a COX-2 inhibitor; 12. using immunosuppressive agents such as cyclosporine, tacrolimus, mycophenolate mofetil were; 13. combined onset of acute suppurative cholangitis; 14. autoimmune pancreatitis, acute exacerbation of chronic pancreatitis or tumor-induced acute pancreatitis; 15. added 3 months before the onset of other clinical trials.

Design outcomes

Primary

Measure	Time frame
Organ failure rate and duration;The rate and duration of abdominal compartment syn;Mortality;	—

Secondary

Measure	Time frame
The recent infection rates;the rate of operation after invalidation;The duration and scores of SIRS;blood routine examination;arterial blood gas analysis;C - reactive protein;procalcitonin;endotoxin;hepatic and renal function;blood glucose;blood glucose;bacteriology;abdominal CT scan;	—

Countries

China

Contacts

Public ContactLiu Pi

liupi1974@sina.com+86 13507913736

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026